Diseases for which medicine offers few effective options-advanced cancer, neurodegenerative diseases, lysosomal storage diseases and autoimmune diseases-persist because they involve very complex and interrelated cellular operations. Bexion is committed to unlocking the workings of the lysosome, the key cellular orchestrator, to provide patients effective, non-toxic therapies where none currently exist.
Bexion Pharmaceuticals President & CEO Ray Takigiku featured on ADVANCEMENTS TV with Ted Danson. In this episode, Advancements will explore how lysosomes play a role in a broad range of diseases including cancer, Alzheimer's, Parkinson's, and even infectious diseases such as viruses and bacteria.
Bexion Pharmaceuticals President & CEO Ray Takigiku featured on ADVANCEMENTS TV with Ted Danson. In this episode, Advancements will explore how lysosomes play a role in a broad range of diseases including cancer, Alzheimer's, Parkinson's, and even infectious diseases such as viruses and bacteria.
Services
Bexion Pharmaceuticals is committed to the discovery and clinical development of life-changing oncology treatments. We leverage over 100 years of life science leadership to accelerate our clinical development program and are driven by the promise of developing life-changing oncology therapies on our path to become a leading biotech/pharmaceutical company.
Bexion believes that lysosome native therapies are an important new tool to fight disease. The overarching mechanisms of cellular regulation and autophagy are at the frontier of our understanding of cellular function and disease, and the lysosome is at the core of this story.
Regulatory dysfunction - including autophagic dysfunction and dysfunction around programmed cell death - lay at the heart of dozens of diseases as disparate as Tay-Sachs and Ebola infections.That the lysosome can be involved in so many different disease and functional pathways, signals at its underlying role as a cellular regulator and orchestrator.
Regulatory dysfunction - including autophagic dysfunction and dysfunction around programmed cell death - lay at the heart of dozens of diseases as disparate as Tay-Sachs and Ebola infections.That the lysosome can be involved in so many different disease and functional pathways, signals at its underlying role as a cellular regulator and orchestrator.
Bioactive sphingolipids (like ceramide) involved in regulation of cancer pathogenesis and therapy. Lysosomes exists as a crucial regulator of cellular function and central to its own function are the Saposins - four proteins that regulate lysosomal enzymes which are responsible for maintaining homeostasis in the cell.
BXQ-350 is the foundation of our pipeline and has demonstrated activity in many different types of cancer mouse models, including glioblastoma and pancreatic cancer. Early clinical results have also shown a strong safety and tolerability profile. There is a critical need for new, safe and effective therapies in Oncology and Bexion is committed to progressing its development through a robust clinical trial program of our novel BXQ-350 franchise.
Before a new therapy can be made available to the general public, multiple studies involving patient volunteers must be conducted to evaluate the safety and effectiveness of the therapy. These studies, referred to as clinical trials, are regulated by the Food and Drug Administration (FDA) in the United States and by similar regulatory agencies worldwide.
Reviews
Be the first to review Bexion Pharmaceuticals.
Write a Review
